Inventor · disambiguated record
Leon Murphy
Also filed as: MURPHY LEON
17 granted patents·16 pending applications·256 citations·filing 2006–2022
94Inventor score
Top patents by PatentIndex Score
33 records- 0197US10174095B2Nucleic acid encoding a humanized anti-BCMA chimeric antigen receptorNOVARTIS AG·Filed 2015·Granted Jan 8, 2019·41 cites·50 claims
- 0297US9815901B2Treatment of cancer using a CD123 chimeric antigen receptorBROGDON JENNIFER·Filed 2015·Granted Nov 14, 2017·94 cites·40 claims
- 0396US10004803B2Low, immune enhancing, dose mtor inhibitors and uses thereofNOVARTIS AG·Filed 2016·Granted Jun 26, 2018·13 cites·11 claims
- 0495US11084880B2Anti-BCMA chimeric antigen receptorNOVARTIS AG·Filed 2018·Granted Aug 10, 2021·15 cites·24 claims
- 0595US10357514B2Treatment of cancer using anti-CD19 Chimeric Antigen ReceptorUNIV PENNSYLVANIA·Filed 2015·Granted Jul 23, 2019·18 cites·45 claims
- 0695US10286069B2Low, immune enhancing, dose MTOR inhibitors and uses thereofNOVARTIS AG·Filed 2018·Granted May 14, 2019·8 cites·11 claims
- 0794US10287354B2Regulatable chimeric antigen receptorNOVARTIS AG·Filed 2014·Granted May 14, 2019·29 cites·63 claims
- 0891US10774388B2Biomarkers predictive of therapeutic responsiveness to chimeric antigen receptor therapy and uses thereofNOVARTIS AG·Filed 2015·Granted Sep 15, 2020·7 cites·31 claims
- 0985US10568947B2Treatment of cancer using a CLL-1 chimeric antigen receptorNOVARTIS AG·Filed 2015·Granted Feb 25, 2020·6 cites·38 claims
- 1083US11578130B2Regulatable chimeric antigen receptorNOVARTIS AG·Filed 2018·Granted Feb 14, 2023·1 cites·30 claims
- 1183US10703819B2Treatment of cancer using a CD123 chimeric antigen receptorNOVARTIS AG·Filed 2017·Granted Jul 7, 2020·1 cites·33 claims
- 1283US9370508B2Imidazoquinolines as dual lipid kinase and mTOR inhibitorsGARCIA-ECHEVERRIA CARLOS·Filed 2008·Granted Jun 21, 2016·13 cites·1 claims
- 1379US2023220090A1Treatment of cancer using a cd123 chimeric antigen receptorNOVARTIS AG·Filed 2022·Application pending·0 cites
- 1476US9358236B2Combinations of therapeutic agents for use in the treatment of neurodegenerative diseasesMURPHY LEON·Filed 2012·Granted Jun 7, 2016·10 cites·4 claims
- 1572US2020054742A1Low, immune enhancing, dose mtor inhibitors and uses thereofNOVARTIS AG·Filed 2019·Application pending·0 cites
- 1672US2015140036A1Low, immune enhancing, dose mtor inhibitors and uses thereofMANNICK JOAN·Filed 2014·Application pending·0 cites
- 1772US2023026049A1Regulatable chimeric antigen receptorNOVARTIS AG·Filed 2022·Application pending·0 cites
- 1870US12214037B2Treatment of cancer using humanized anti-BCMA chimeric antigen receptorUNIV PENNSYLVANIA·Filed 2021·Granted Feb 4, 2025·0 cites·16 claims
- 1970US11591404B2Treatment of cancer using a CD123 chimeric antigen receptorNOVARTIS AG·Filed 2020·Granted Feb 28, 2023·0 cites·33 claims
- 2070US2023052970A1Phosphoglycerate kinase 1 (pgk) promoters and methods of use for expressing chimeric antigen receptorNOVARTIS AG·Filed 2022·Application pending·0 cites
- 2165US2020215171A1Treatment of cancer using a cll-1 chimeric antigen receptorNOVARTIS AG·Filed 2019·Application pending·0 cites
- 2264US2020339651A1Methods for b cell preconditioning in car therapyNOVARTIS AG·Filed 2019·Application pending·0 cites
- 2362US2019388471A1Treatment of cancer using anti-cd19 chimeric antigen receptorNOVARTIS AG·Filed 2019·Application pending·0 cites
- 2462US2021172020A1Biomarkers predictive of therapeutic responsiveness to chimeric antigen receptor therapy and uses thereofNOVARTIS AG·Filed 2020·Application pending·0 cites
- 2556US2023272392A1Methods of tfeb activation and lysosomal biogenesis and compositions thereforCASMA THERAPEUTICS INC·Filed 2021·Application pending·0 cites
- 2654US11459390B2Phosphoglycerate kinase 1 (PGK) promoters and methods of use for expressing chimeric antigen receptorNOVARTIS AG·Filed 2016·Granted Oct 4, 2022·0 cites·21 claims
- 2754US2021030741A1Pharmaceutical combination of everolimus with dactolisibNOVARTIS AG·Filed 2019·Application pending·0 cites
- 2854US2017274014A1Combinations of low, immune enhancing, doses of mtor inhibitors and carsBROGDON JENNIFER·Filed 2014·Application pending·0 cites
- 2951US10576076B2Pharmaceutical combination of everolimus with dactolisibGLASS DAVID·Filed 2016·Granted Mar 3, 2020·0 cites·21 claims
- 3051US2018334490A1Methods for b cell preconditioning in car therapyBROGDON JENNIFER·Filed 2015·Application pending·0 cites
- 3143US2007173472A1Methods and reagents for the treatment of apoptosis-related disordersNOVARTIS AG·Filed 2006·Application pending·0 cites
- 3238US2013178479A1Pharmaceutical combinationsCHEN YAN·Filed 2011·Application pending·0 cites
- 3337US2009258929A1Compositions and Methods for Modulating mTOR SignalingFINAN PETER·Filed 2007·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Leon Murphy files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →